TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36104664

Group type: EXPERIMENTAL
Intervention: Auto-titrating positive airway pressure (APAP) for 72 hours postoperatively or until discharge
Number of subjects: 234

Group type: COMPARATOR
Intervention: Routine care after surgery
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 234

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 234

Group type: COMPARATOR
Intervention: APAP vs. Routine care
Number of subjects: 234
Study: 34127046

Group type: EXPERIMENTAL
Intervention: Awake prone positioning (16 hours per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study: 34173063

Group type: EXPERIMENTAL
Intervention: OMIS + NRCT + NDT‐B (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: OMIS + NRCT (n = 20)
Number of subjects: 40
Study: 36363460

Group type: EXPERIMENTAL
Intervention: Ormeloxifene
Number of subjects: 367

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate
Number of subjects: 367
Study: 32250057

Group type: EXPERIMENTAL
Intervention: Remimazolam (single intravenous injection)
Number of subjects: 62
Study: 33032771

Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 35394678

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA-IM)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: All groups with low baseline inflammation
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: All groups with high baseline inflammation
Number of subjects: 161
Study: 32978200

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg or 150 mg two times per day
Number of subjects: 686

Group type: COMPARATOR
Intervention: Warfarin with international normalised ratio 2-3
Number of subjects: 686
Study: 35552386

Group type: EXPERIMENTAL
Intervention: LED-mediated photobiomodulation (PBM) with 850 nm wavelength, 60 mW/cm2 power, continuous LED illumination for 5 minutes/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no LED treatment)
Number of subjects: 20
Study: 33408282

Group type: EXPERIMENTAL
Intervention: 2-hourly feeding schedule
Number of subjects: 350

Group type: COMPARATOR
Intervention: 3-hourly feeding schedule
Number of subjects: 350
Study: 32041644

Group type: EXPERIMENTAL
Intervention: High-dose EAA/protein composition (12.6g protein, 3.2g EAA per serving)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose EAA/protein composition (6.3g protein, 1.6g EAA per serving)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gatorade Recover (17g; 12.6g protein)
Number of subjects: 0
Study: 36123932

Group type: EXPERIMENTAL
Intervention: Dynamic balance exercise (DBE)
Number of subjects: 36
Study: 33247575

Group type: EXPERIMENTAL
Intervention: Binaural beats (220 Hz for right ear, 210 Hz for left ear) for 10 minutes
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 432 Hz tuned music for 10 minutes
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 32202262

Group type: EXPERIMENTAL
Intervention: Lower trapezius strengthening exercise program, applied 3 times per week for 4 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Scapula and thoracic spine stabilization exercise program (same for both groups).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lower trapezius strengthening exercise program.
Number of subjects: 40
Study: 35506577

Group type: EXPERIMENTAL
Intervention: Incenter Brochure plus Email
Number of subjects: 0

Group type: COMPARATOR
Intervention: Email Only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 34436509

Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg/d) + standard of care (SOC: 40 mg dihydroartemisinin + 320 mg piperaquine/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC: 40 mg dihydroartemisinin + 320 mg piperaquine/d)
Number of subjects: 0
Study: 34875022

Group type: EXPERIMENTAL
Intervention: High-dose intravenous iron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose intravenous iron
Number of subjects: 0
Study: 33638612

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor allele carriers (A/A) of rs9827586
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor allele carriers (A/A) of rs701109
Number of subjects: 0
Study: 33829920

Group type: EXPERIMENTAL
Intervention: Daily sustained physical activity (PA)
Number of subjects: 277
Study: 32235773

Group type: EXPERIMENTAL
Intervention: Milk Protein Isolate (MPI) - 0.7 g protein/kg/d
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (CON) - 0.7 g carbohydrate/kg/d
Number of subjects: 44
Study: 33945886

Group type: EXPERIMENTAL
Intervention: Self-affirmation followed by gain-framed health messages daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Daily loss-framed health messages only
Number of subjects: 80
Study: 34799275

Group type: EXPERIMENTAL
Intervention: Individualized follitropin delta dosing
Number of subjects: 800
Study: 33984356

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both Yoga and CBT
Number of subjects: 75
Study: 35060389

Group type: EXPERIMENTAL
Intervention: Low BMI (<20 kg/m2; n=244)
Number of subjects: 15828

Group type: EXPERIMENTAL
Intervention: High BMI (≥35 kg/m2; n=1768)
Number of subjects: 15828

Group type: EXPERIMENTAL
Intervention: BMI between 20 and <25 kg/m2
Number of subjects: 15828

Group type: COMPARATOR
Intervention: BMI of 25 to 35 kg/m2
Number of subjects: 15828
Study: 33144049

Group type: EXPERIMENTAL
Intervention: PPAA (polaprezinc in polyacrylic acid solution)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (without PPAA)
Number of subjects: 120
Study: 35512757

Group type: EXPERIMENTAL
Intervention: Amylose-resistant starch (RS) supplementation, 16g/d for 4 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 35162761

Group type: EXPERIMENTAL
Intervention: Physio‐EndEA program (therapeutic exercise program focused on lumbopelvic stabilization and tolerance to exertion)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Physio‐EndEA program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 22
Study: 32312344

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 151

Group type: COMPARATOR
Intervention: Escitalopram and Desvenlafaxine
Number of subjects: 151
Study: 32018252

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study: 35157493

Group type: EXPERIMENTAL
Intervention: Single dose of BNT162b2 vaccine
Number of subjects: 107413

Group type: COMPARATOR
Intervention: No vaccination
Number of subjects: 107413
Study: 34112656

Group type: COMPARATOR
Intervention: Usual escalation (5 mg every 4 weeks)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Fast escalation (5 mg every 2 weeks)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual escalation
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Fast escalation
Number of subjects: 178
Study: 32925765

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise training
Number of subjects: 192

Group type: COMPARATOR
Intervention: Basic treatment (health education and Tiotropium bromide)
Number of subjects: 192
Study: 36139001

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 2 mA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study: 33225995

Group type: EXPERIMENTAL
Intervention: Once weekly self-collected oral swabs (OS) regardless of symptoms
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Once weekly self-collected oral-nares swab (O-NS) regardless of symptoms
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Once weekly nurse collected nasopharyngeal swab (NPS) regardless of symptoms
Number of subjects: 400

Group type: COMPARATOR
Intervention: Active daily surveillance of symptoms and testing only in symptomatic participants (comparator group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: All intervention arms
Number of subjects: 400
Study: 33029804

Group type: EXPERIMENTAL
Intervention: Single-layer closure technique
Number of subjects: 225

Group type: COMPARATOR
Intervention: Double-layer closure technique
Number of subjects: 225
Study: 35997003

Group type: EXPERIMENTAL
Intervention: 50% mandibular advancement
Number of subjects: 32

Group type: COMPARATOR
Intervention: 75% mandibular advancement
Number of subjects: 32
Study: 34837992

Group type: EXPERIMENTAL
Intervention: Modified sutureless and glue-free method
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 52
Study: 32557731

Group type: EXPERIMENTAL
Intervention: Minimal invasive extracorporeal circulation (MiECC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 240
Study: 35779328

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham control interview (CI)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Participants who attended at least one training session (regardless of randomization)
Number of subjects: 114
Study: 32446172

Group type: EXPERIMENTAL
Intervention: Participatory group-based care management
Number of subjects: 392

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 392
Study: 35641327

Group type: EXPERIMENTAL
Intervention: Contemporary new-generation stents
Number of subjects: 9204
Study: 35109416

Group type: EXPERIMENTAL
Intervention: Digital application-supported compensation training and lifestyle modification intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Education only control group (no use of EMMA app)
Number of subjects: 200
Study: 32883322

Group type: COMPARATOR
Intervention: Placebo plus 5-day prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus 9-day prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JWBY formulas plus 5-day prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JWBY formulas plus 9-day prednisone
Number of subjects: 0
Study: 34667294

Group type: EXPERIMENTAL
Intervention: CVN058 150 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CVN058 (combined analysis across all MMN deviants)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CVN058 (location MMN)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34052211

Group type: EXPERIMENTAL
Intervention: RDN using the Peregrine Kit with alcohol (0.6 mL per renal artery)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Diagnostic renal angiography only (sham procedure)
Number of subjects: 396
Study: 33135737

Group type: COMPARATOR
Intervention: LEAP238-47 infusion in healthy human individuals (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LEAP238-47
Number of subjects: 20
Study: 32476624

Group type: EXPERIMENTAL
Intervention: Efficacy-focused 'Quit' label
Number of subjects: 398

Group type: COMPARATOR
Intervention: Threat-focused warning labels
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Efficacy-focused 'Quit' label within a set of threat-focused labels
Number of subjects: 398
Study: 35134170

Group type: EXPERIMENTAL
Intervention: Dulaglutide (Trulicity) 1.5 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 54
Study: 33412128

Group type: EXPERIMENTAL
Intervention: Transabdominal and transperineal ultrasound assessments
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Prediction model developed from ultrasound assessments
Number of subjects: 344
Study: 33969466

Group type: EXPERIMENTAL
Intervention: Surgical resection of colorectal PM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized prognostic variables (Peritoneal Cancer Index, Completeness of Cytoreduction Score)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second look surgery with oxaliplatin HIPEC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic oxaliplatin HIPEC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxaliplatin HIPEC with CRS of colorectal PM
Number of subjects: 0
Study: 33832544

Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 203

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 203
Study: 32818525

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA, 30 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tACS (2 mA, 30 min, 40 Hz frequency)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60
Study: 36354718

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (100 mg adjunct testosterone, seven weekly injections)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 24
Study: 32586361

Group type: EXPERIMENTAL
Intervention: Bilateral TQL block with 30 ml ropivacaine 0.375% each on both sides plus postoperative patient-controlled intravenous analgesia with morphine (TQL group, n=75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Bilateral TQL block with 30 ml saline each on both sides plus postoperative patient-controlled intravenous analgesia with morphine (placebo group, n=75)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: TQL group
Number of subjects: 150
Study: 34856563

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 59
Study: 33583740

Group type: EXPERIMENTAL
Intervention: Amoxicillin administered 24 hours pre-operatively
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Amoxicillin administered 48 hours pre-operatively
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Amoxicillin (250 mg/dose every 8 h x 3 doses beginning 1 h before surgery)
Number of subjects: 340
Study: 33757937

Group type: EXPERIMENTAL
Intervention: Foley catheter with concurrent oxytocin administration
Number of subjects: 151

Group type: COMPARATOR
Intervention: Foley catheter only
Number of subjects: 151
Study: 32367416

Group type: EXPERIMENTAL
Intervention: Spectral CT
Number of subjects: 503

Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 503
Study: 36097565

Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation (combination of TCM and Western conventional rehabilitation methods including acupuncture, repeated transcranial magnetic stimulation, traditional Chinese herbal medicine, and standard care)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation
Number of subjects: 188
Study: 34321316

Group type: EXPERIMENTAL
Intervention: SCO-267 (GPR40 full agonist)
Number of subjects: 0
Study: 33052382

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 997

Group type: COMPARATOR
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 997

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997
Study: 35857127

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy for metastatic breast cancer
Number of subjects: 0
Study: 33568088

Group type: EXPERIMENTAL
Intervention: Prognostic score (PS) based on pTNM stage, number of lymph nodes (NLNs), and PD-L1 expression.
Number of subjects: 153

Group type: COMPARATOR
Intervention: Prognostic score (PS) system
Number of subjects: 153
Study: 36177837

Group type: EXPERIMENTAL
Intervention: Total Pancreatectomy with Islet AutoTransplantation (TP-IAT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Pancreaticoduodenectomy (PD)
Number of subjects: 61
Study: 35438799

Group type: EXPERIMENTAL
Intervention: Naltrexone opioid blockade
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32559272

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/d for 24 weeks)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 34602349

Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin (GC, 4 cycles)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: cisplatin (mandatory minimum total dose of 270 mg/m2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: cisplatin-based chemotherapy (at least 4 cycles)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: cisplatin (full doses given in 1866 cycles, 88%)
Number of subjects: 23
Study: 34191424

Group type: EXPERIMENTAL
Intervention: Improved B-ultrasound method (B method)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Physicians' clinical experience (control group)
Number of subjects: 64
Study: 35245813

Group type: EXPERIMENTAL
Intervention: Visual EMG biofeedback
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Auditory biofeedback
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Verbal cues biofeedback
Number of subjects: 15
Study: 32723264

Group type: EXPERIMENTAL
Intervention: 12 mg sublingual melatonin the evening before and 1 hour before surgery
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no melatonin)
Number of subjects: 76
Study: 32773013

Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 1643

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1643
Study: 35686812

Group type: EXPERIMENTAL
Intervention: Percutaneous ablation therapy (AT)
Number of subjects: 2276

Group type: COMPARATOR
Intervention: Partial nephrectomy (PN)
Number of subjects: 2276
Study: 34096894

Group type: EXPERIMENTAL
Intervention: Letrozole treatment
Number of subjects: 228

Group type: COMPARATOR
Intervention: Exemestane treatment
Number of subjects: 228
Study: 32198638

Group type: EXPERIMENTAL
Intervention: Top Surgery Scar go (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Silicone gel (Group B)
Number of subjects: 30
Study: 32658597

Group type: COMPARATOR
Intervention: Traditional 1RM testing (BT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Novel technique (TDT)
Number of subjects: 70
Study: 32489264

Group type: EXPERIMENTAL
Intervention: elcss-ql arm (real-time electronic Lung Cancer Symptom Scale data provided to oncologists)
Number of subjects: 95

Group type: COMPARATOR
Intervention: standard arm (standard clinical assessment without elcss-ql data)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: elcss-ql arm
Number of subjects: 95

Group type: COMPARATOR
Intervention: standard arm
Number of subjects: 95
Study: 35963369

Group type: EXPERIMENTAL
Intervention: Ivarmacitinib 8 mg QD
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ivarmacitinib 4 mg BID
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ivarmacitinib 4 mg QD
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 33151422

Group type: EXPERIMENTAL
Intervention: Buffered 2% articaine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-buffered 4% articaine
Number of subjects: 2
Study: 32097388

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Both PCI and CABG
Number of subjects: 840
Study: 35457509

Group type: EXPERIMENTAL
Intervention: HBV knowledge
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: CHB-management motivation
Number of subjects: 382
Study: 32889329

Group type: EXPERIMENTAL
Intervention: Endometrial scratch injury
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no endometrial scratch injury)
Number of subjects: 150
Study: 35061166

Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR) intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waitlist-control group (typical EHS services)
Number of subjects: 102
Study: 33620725

Group type: EXPERIMENTAL
Intervention: Preventive interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 32206810

Group type: EXPERIMENTAL
Intervention: Heart age + conventional risk communication (intervention)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Conventional risk communication (control)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 378
Study: 35920250

Group type: EXPERIMENTAL
Intervention: Low-dose magnesium sulfate solution (MSS)
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Standard polyethylene glycol (PEG)
Number of subjects: 1174
Study: 32533045

Group type: EXPERIMENTAL
Intervention: General Sleep Disturbance Scale (GSDS-IT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 57
Study: 35082252

Group type: EXPERIMENTAL
Intervention: Focused attention mindfulness
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Sham
Number of subjects: 153

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Expectation for pain relief (told mindfulness)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Belief of receiving mindfulness
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Expectancy
Number of subjects: 153
Study: 33168369

Group type: EXPERIMENTAL
Intervention: Intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 98
Study: 32070395

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) administered at a loading dose of 1 g, followed by 1 g every 8 hours for a maximum of 24 hours, in addition to standard care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study: 33555824

Group type: EXPERIMENTAL
Intervention: Hydrogen rich water (HRW)
Number of subjects: 12
Study: 33415606

Group type: EXPERIMENTAL
Intervention: Viscotrabeculotomy
Number of subjects: 148

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 148